- In August 2022, ARTHEx Biotech launched ENTRY, a platform designed to advance its drug pipeline, which includes treatments for myotonic dystrophy, cancer cachexia, and osteoarthritis, by enabling tissue-enriched delivery of antimiRs
- In June 2022, A research team led by Rutgers Cancer Institute of New Jersey secured a USD 25 million Cancer Grand Challenges grant to investigate cancer cachexia, a debilitating condition often seen in the later stages of cancer
- In April 2021, Helsinn, a Swiss pharmaceutical company, in partnership with Ono Pharmaceutical, launched Adlumiz Tablets in Japan to treat cancer cachexia associated with malignant non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer
- In April 2021, Actimed Therapeutics Ltd entered into a license agreement with Faraday Pharmaceuticals, Inc. for S-oxprenolol, and Faraday acquired global rights to develop and commercialize the drug for cancer cachexia, with Actimed eligible for royalties on future sales
- In February 2021, Researchers from Trinity announced a partnership with Artelo Biosciences to expand research and explore new treatment options for cancer cachexia
